Vidofludimus (BioDeep_00000837655)
代谢物信息卡片
化学式: C20H18FNO4 (355.12198)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
InChI: InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
描述信息
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY
C471 - Enzyme Inhibitor > C2169 - Dihydroorotate Dehydrogenase Inhibitor
C308 - Immunotherapeutic Agent > C574 - Immunosuppressant
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yuanying Fang, Lamees Hegazy, Brian N Finck, Bahaa Elgendy. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
Journal of medicinal chemistry.
2021 12; 64(24):17545-17571. doi:
10.1021/acs.jmedchem.1c01017. [PMID: 34889100] - Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
European journal of drug metabolism and pharmacokinetics.
2020 Oct; 45(5):557-573. doi:
10.1007/s13318-020-00623-7. [PMID: 32361977] - Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Multiple sclerosis and related disorders.
2020 Aug; 43(?):102129. doi:
10.1016/j.msard.2020.102129. [PMID: 32428844] - Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt. The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
Drugs in R&D.
2019 Dec; 19(4):351-366. doi:
10.1007/s40268-019-00286-z. [PMID: 31621054] - K R Herrlinger, M Diculescu, K Fellermann, H Hartmann, S Howaldt, R Nikolov, A Petrov, W Reindl, J M Otte, S Stoynov, U Strauch, A Sturm, R Voiosu, A Ammendola, B Dietrich, B Hentsch, E F Stange. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Journal of Crohn's & colitis.
2013 Sep; 7(8):636-43. doi:
10.1016/j.crohns.2012.09.016. [PMID: 23078909] - Krisztina Rusai, Christoph Schmaderer, Marcus Baumann, Stefan Chmielewski, Agnes Prókai, Eva Kis, Attila J Szabó, Johann Leban, Robert Doblhofer, Aldo Ammendola, Jens Lutz, Uwe Heemann. Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation.
Transplantation.
2012 Jun; 93(11):1101-7. doi:
10.1097/tp.0b013e31824fd861. [PMID: 22609757] - Onkar P Kulkarni, Sufyan G Sayyed, Claudia Kantner, Mi Ryu, Max Schnurr, Miklós Sárdy, Johann Leban, Ruediger Jankowsky, Aldo Ammendola, Robert Doblhofer, Hans-Joachim Anders. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
The American journal of pathology.
2010 Jun; 176(6):2840-7. doi:
10.2353/ajpath.2010.091227. [PMID: 20413687]